Quarterly report [Sections 13 or 15(d)]

CONSOLIDATED SCHEDULE OF INVESTMENTS (Parenthetical)

v3.25.1
CONSOLIDATED SCHEDULE OF INVESTMENTS (Parenthetical)
$ in Thousands
Mar. 31, 2025
USD ($)
firm
Dec. 31, 2024
USD ($)
firm
Investment Holding [Line Items]    
Investment, basis spread, variable rate 7.50% 7.50%
Aggregate gross unrealized appreciation $ 110,700 $ 108,400
Aggregate gross unrealized depreciation 181,000 156,500
Net unrealized appreciation (depreciation) over cost for U.S. federal income tax purposes (70,300) (48,100)
Aggregate cost of securities for U.S. federal income tax purposes (in billions) 4,000,000 3,700,000
Investment cost 3,995,082 3,708,877
Investments, at fair value: $ 3,924,450 $ 3,659,978
1-month SOFR    
Investment Holding [Line Items]    
Interest rate 4.32% 4.33%
3-month SOFR    
Investment Holding [Line Items]    
Interest rate 4.29% 4.31%
6-month SOFR    
Investment Holding [Line Items]    
Interest rate 4.19% 4.25%
Common Stock | Significant Other Observable Inputs (Level 2)    
Investment Holding [Line Items]    
Number of publicly traded companies | firm 28 28
Warrants | Quoted Prices in Active Markets for Identical Assets (Level 1)    
Investment Holding [Line Items]    
Number of publicly traded companies | firm 21 23
Black Crow AI, Inc. affiliates | Promissory Note    
Investment Holding [Line Items]    
Principal amount $ 2,400 $ 2,400
Akero Therapeutics, Inc. | Royalty Contract    
Investment Holding [Line Items]    
Investment cost 11,900 11,900
Investments, at fair value: $ 11,700 $ 11,600